Leishmaniasis visceral, estudio de casos

  1. Momeñe-Rojas, Natalia-Ane 1
  2. Pereda-Barroeta, Javier 1
  3. Villamandos-Tellaeche, Edorta 1
  4. Franco-Vicario, Ricardo 1
  1. 1 Servicio Vasco de Salud-Osakidetza. Organización Sanitaria Integrada Bilbao – Basurto. Hospital Universitario Basurto. Servicio de Medicina Interna. Bilbao, España.
Aldizkaria:
Gaceta médica de Bilbao: Revista oficial de la Academia de Ciencias Médicas de Bilbao. Información para profesionales sanitarios

ISSN: 0304-4858,  2173-2302

Argitalpen urtea: 2023

Alea: 120

Zenbakia: 3

Orrialdeak: 138-142

Mota: Artikulua

DIALNET GOOGLE SCHOLAR lock_openSarbide irekia editor

Beste argitalpen batzuk: Gaceta médica de Bilbao: Revista oficial de la Academia de Ciencias Médicas de Bilbao. Información para profesionales sanitarios

Laburpena

Background and objective: Leishmaniasis is a parasitic disease endemic in tropical or subtropical areas, including the Mediterranean basin. Visceral Leishmaniasis or Kala Azar is the most serious form. In our area, the incidence is low due to the absence of vectors, but cases can be seen in relation to migration, generally in immunocompromised patients and children. The objective of this article is to review the cases of Visceral Leishmaniasis reported in two tertiary hospitals in Biscay in recent years in order to correlate them with the epidemiological situation.Results and conclusions: Most of the reported cases were HIV-positive patients, with a greater proportion being registered before the year 2000. It is notable that since the introduction of HAART in 1997 there has been a marked decrease in the number of cases. Despite this, it is important to suspect it when faced with clinical pictures compatible with relevant epidemiological history.

Erreferentzia bibliografikoak

  • Pigott DM, Bhatt S, Golding N, Duda KA, Battle KE, Brady OJ, et al. Global dis-tribution maps of the leishmaniases. Tollman S, editor. eLife. 2014;3:e02851.
  • WHO Global leishmaniasis update, 2006–2015: a turning point in leishmaniasis sur-veillance [Internet]. WHO. [citado 6 de agosto de 2019]. Disponible en: http://www.who.int/leishmaniasis/resources/who_wer9238/en/
  • Oryan A, Akbari M. Worldwide risk factors in leishmaniasis. Asian Pac J Trop Med. 2016;9(10):925-32.
  • Burza S, Croft SL, Boelaert M. Leishmaniasis. The Lancet. 2018;392(10151):951-70.
  • Molina R, Jiménez MI, Cruz I, Iriso A, Martín-Martín I, Sevillano O, et al. The hare (Lepus granatensis) as potential sylvatic reservoir of Leishmania infantum in Spain. Vet Parasitol. 2012;190(1-2):268-71.
  • Monge-Maillo B, Norman FF, Cruz I, Alvar J, López-Vélez R. Visceral leishmania-sis and HIV coinfection in the Mediterranean region. PLoS Negl Trop Dis. 2014;8(8):e3021.
  • Antinori S, Cascio A, Parravicini C, Bianchi R, Corbellino M. Leishmaniasis among organ transplant recipients. Lancet Infect Dis. 2008;8(3):191-9.
  • Phlebotomine sandflies maps [Internet]. European Centre for Disease Prevention and Control. [citado 6 de agosto de 2019]. Disponible en: http://ecdc.europa.eu/en/disease-vectors/surveillance-and-disease-data/phlebotomine-maps
  • Alten B, Maia C, Afonso MO, Campino L, Jiménez M, González E, et al. Seasonal Dynamics of Phlebotomine Sand Fly Species Proven Vectors of Mediterranean Leishmaniasis Caused by Leishmania infantum. PLoS Negl Trop Dis [Internet]. 22 de febrero de 2016 [citado 9 de agosto de 2019];10(2). Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762948/
  • Herrador Z, Gherasim A, Jimenez BC, Granados M, San Martín JV, Aparicio P. Ep-idemiological Changes in Leishmaniasis in Spain According to Hospitalization-Based Records, 1997–2011: Raising Awareness towards Leishmaniasis in Non-HIV Patients. PLoS Negl Trop Dis. 2015;9(3).
  • Velez R, Ballart C, Domenech E, Abras A, Fernández- Arévalo A, Gómez SA, et al. Seroprevalence of canine Leishmania infantum infection in the Mediterranean region and identification of risk factors: The example of North-Eastern and Pyrenean areas of Spain. Prev Vet Med. 2019; 162:67-75.
  • Martínez BF, Barroso DG, Portero RC. La leishmaniasis en España: evolución de los casos notificados a la Red Nacional de Vigilancia Epidemiológica desde 2005 a 2017 y resultados de la vigilancia de 2014 a 2017. Boletín epidemiológico semanal. 2019;27(2):15-27.
  • Queiroz A, Sousa R, Heine C, et al. Association between an emerging disseminated form of leishmaniasis and Leishmania (Viannia) braziliensis strain polymorphisms. J Clin Microbiol. 2012; 50:4028.
  • Bogdan C. Leishmaniasis in rheumatology, haematology and oncology: epidemio-logical, immunological and clinical aspects and caveats. Ann Rheum Dis. 2012;71Suppl2:i60.
  • Zijlstra EE, Ali MS, el-Hassan AM, et al. Kala-azar: a comparative study of parasi-tological methods and the direct agglutination test in diagnosis. Trans R Soc Trop Med Hyg. 1992; 86:505.
  • Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. J Clin Microbiol. 2007; 45:21.
  • Sundar S, Singh A. Recent developments and future prospects in the treatment of visceral leishmaniasis. Ther Adv Infect Dis. 2016; 3:98.
  • Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2016; 63:e202.
Datuen iturria: Dialnet